A. Nachtnebel

Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab

Caridad Pontes, Corinne Zara, Josep Torrent-Farnell et al. · Applied Health Economics and Health Policy · 2019 · 34 citations

Oncology, New Cancer Medicines, Cancer Management +7

Disinvestment. Overview of disinvestment experiences and challenges in selected countries

J. Gerdvilaite, A. Nachtnebel · 2011 · 23 citations

Healthcare Provision, International Investment, Policy Analysis +22

Scanning the horizon—Development and implementation of an early awareness system for anticancer drugs in Austria

A. Nachtnebel, S. Geiger-Gritsch, K. Hintringer et al. · Health Policy · 2011 · 21 citations

Drug Safety, Preventive Medicine, Anticancer Drugs +6

COLLABORATION IN HEALTH TECHNOLOGY ASSESSMENT (EU<scp>net</scp>HTA JOINT ACTION, 2010–2012): FOUR CASE STUDIES

Mirjana Huić, A. Nachtnebel, Ingrid Zechmeister‐Koss et al. · International Journal of Technology Assessment in Health Care · 2013 · 17 citations

Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements

Hans‐Georg Eichler, Róisín Adams, Einar Andreassen et al. · International Journal of Technology Assessment in Health Care · 2021 · 16 citations · Full text

Law, Other Caprs, Management +21